Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells

Florian Hohla, Stefan Buchholz, Andrew V Schally, Awtar Krishan, Ferenc G. Rick, Luca Szalontay, Andrea Papadia, Gabor Halmos, Frank Koster, Elmar Aigner, Christian Datz, Stephan Seitz

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The effect of the targeted cytotoxic somatostatin (SST) analog AN-162, consisting of doxorubicin (DOX) conjugated to SST carrier RC-121, was investigated on the growth of human colorectal cancer (CRC) cell lines HT-29, HCT-15, and HCT-116 and a DOX-resistant mouse leukemia cell line P388/R84. mRNA for SST-receptors and high affinity binding sites for SST were detected in all CRC cell lines and in P388/R84 cells. In contrast to DOX alone, AN-162 blocked HCT-116 cells and P388/R84 cells in S/G2 phase and increased the number of apoptotic cells. In vivo, AN-162 reduced the volume of CRC xenografts more effectively than its unconjugated components. Our results suggest that AN-162 inhibits growth of experimental CRC more effectively than DOX and increases sensitivity of DOX resistant human leukemia cells.

Original languageEnglish
Pages (from-to)35-42
Number of pages8
JournalCancer Letters
Volume294
Issue number1
DOIs
StatePublished - Aug 1 2010

Fingerprint

Somatostatin
Doxorubicin
Colon
Leukemia
Colorectal Neoplasms
Carcinoma
Growth
Cell Line
HCT116 Cells
Somatostatin Receptors
G2 Phase
S Phase
Heterografts
Cell Count
Binding Sites
N-(2-diethylaminoethyl)-N-(2-hydroxy-2-phenylethyl)-2,5-dichloroaniline
Messenger RNA

Keywords

  • AN-162
  • Colon cancer
  • Doxorubicin
  • Somatostatin
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. / Hohla, Florian; Buchholz, Stefan; Schally, Andrew V; Krishan, Awtar; Rick, Ferenc G.; Szalontay, Luca; Papadia, Andrea; Halmos, Gabor; Koster, Frank; Aigner, Elmar; Datz, Christian; Seitz, Stephan.

In: Cancer Letters, Vol. 294, No. 1, 01.08.2010, p. 35-42.

Research output: Contribution to journalArticle

Hohla, F, Buchholz, S, Schally, AV, Krishan, A, Rick, FG, Szalontay, L, Papadia, A, Halmos, G, Koster, F, Aigner, E, Datz, C & Seitz, S 2010, 'Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells', Cancer Letters, vol. 294, no. 1, pp. 35-42. https://doi.org/10.1016/j.canlet.2010.01.018
Hohla, Florian ; Buchholz, Stefan ; Schally, Andrew V ; Krishan, Awtar ; Rick, Ferenc G. ; Szalontay, Luca ; Papadia, Andrea ; Halmos, Gabor ; Koster, Frank ; Aigner, Elmar ; Datz, Christian ; Seitz, Stephan. / Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. In: Cancer Letters. 2010 ; Vol. 294, No. 1. pp. 35-42.
@article{cfaf46ae01d14b799c50ff0cb3bc604d,
title = "Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells",
abstract = "The effect of the targeted cytotoxic somatostatin (SST) analog AN-162, consisting of doxorubicin (DOX) conjugated to SST carrier RC-121, was investigated on the growth of human colorectal cancer (CRC) cell lines HT-29, HCT-15, and HCT-116 and a DOX-resistant mouse leukemia cell line P388/R84. mRNA for SST-receptors and high affinity binding sites for SST were detected in all CRC cell lines and in P388/R84 cells. In contrast to DOX alone, AN-162 blocked HCT-116 cells and P388/R84 cells in S/G2 phase and increased the number of apoptotic cells. In vivo, AN-162 reduced the volume of CRC xenografts more effectively than its unconjugated components. Our results suggest that AN-162 inhibits growth of experimental CRC more effectively than DOX and increases sensitivity of DOX resistant human leukemia cells.",
keywords = "AN-162, Colon cancer, Doxorubicin, Somatostatin, Targeted therapy",
author = "Florian Hohla and Stefan Buchholz and Schally, {Andrew V} and Awtar Krishan and Rick, {Ferenc G.} and Luca Szalontay and Andrea Papadia and Gabor Halmos and Frank Koster and Elmar Aigner and Christian Datz and Stephan Seitz",
year = "2010",
month = "8",
day = "1",
doi = "10.1016/j.canlet.2010.01.018",
language = "English",
volume = "294",
pages = "35--42",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells

AU - Hohla, Florian

AU - Buchholz, Stefan

AU - Schally, Andrew V

AU - Krishan, Awtar

AU - Rick, Ferenc G.

AU - Szalontay, Luca

AU - Papadia, Andrea

AU - Halmos, Gabor

AU - Koster, Frank

AU - Aigner, Elmar

AU - Datz, Christian

AU - Seitz, Stephan

PY - 2010/8/1

Y1 - 2010/8/1

N2 - The effect of the targeted cytotoxic somatostatin (SST) analog AN-162, consisting of doxorubicin (DOX) conjugated to SST carrier RC-121, was investigated on the growth of human colorectal cancer (CRC) cell lines HT-29, HCT-15, and HCT-116 and a DOX-resistant mouse leukemia cell line P388/R84. mRNA for SST-receptors and high affinity binding sites for SST were detected in all CRC cell lines and in P388/R84 cells. In contrast to DOX alone, AN-162 blocked HCT-116 cells and P388/R84 cells in S/G2 phase and increased the number of apoptotic cells. In vivo, AN-162 reduced the volume of CRC xenografts more effectively than its unconjugated components. Our results suggest that AN-162 inhibits growth of experimental CRC more effectively than DOX and increases sensitivity of DOX resistant human leukemia cells.

AB - The effect of the targeted cytotoxic somatostatin (SST) analog AN-162, consisting of doxorubicin (DOX) conjugated to SST carrier RC-121, was investigated on the growth of human colorectal cancer (CRC) cell lines HT-29, HCT-15, and HCT-116 and a DOX-resistant mouse leukemia cell line P388/R84. mRNA for SST-receptors and high affinity binding sites for SST were detected in all CRC cell lines and in P388/R84 cells. In contrast to DOX alone, AN-162 blocked HCT-116 cells and P388/R84 cells in S/G2 phase and increased the number of apoptotic cells. In vivo, AN-162 reduced the volume of CRC xenografts more effectively than its unconjugated components. Our results suggest that AN-162 inhibits growth of experimental CRC more effectively than DOX and increases sensitivity of DOX resistant human leukemia cells.

KW - AN-162

KW - Colon cancer

KW - Doxorubicin

KW - Somatostatin

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77953027756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953027756&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2010.01.018

DO - 10.1016/j.canlet.2010.01.018

M3 - Article

VL - 294

SP - 35

EP - 42

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -